From: Botulinum neurotoxin type A for the treatment of pain: not just in migraine and trigeminal neuralgia
Condition | Subjects | Studies | Comparator | Outcomea | Ref. |
---|---|---|---|---|---|
EM | 1838 | 9 | Placebo | n.s. | 18 |
CM | 1508 | 5 | Placebo | HEPM: −2.30 [95% CI: −3.7, −0.9] | 18 |
59 | 1 | Topiramate | n.s. | 18 | |
72 | 1 | Amitriptyline | n.s. | 18 | |
CDH | 1115 | 1 | Placebo | HEPM: −2.1 [95% CI: −3.6, −0.6] | 18 |
Any TTH | 59 | 1 | Valproate | n.s. | 18 |
21 | 1 | Steroids | HEPM: −2.5 [95% CI:−3.5, −1.5] | 18 | |
Chronic TTH | 675 | 7 | Placebo | n.s. | 18 |
TMD | 145 | 4 | Placebo | Meta-analysis not performed | 22 |
30 | 1 | Manipulation | n.s. | 22 | |
CNPb | 371 | 8 | Placebo | Little or no difference | 23 |
CCH | 32 | 1 | Placebo | Little or no difference | 23 |
Whiplash | 96 | 3 | Placebo | n.s. | 24 |
TN | 178 | 4 | Placebo | PPD: −29.8 [95% CI:−38.5, −21.1] | 8 |
Diabetic NP | 76 | 2 | Placebo | 0–10 VAS: −2.0 [95% CI:−3.1, −0.8] | 27 |
Peripheral NP | 68 | 1 | Placebo | 0–10 NRS:-0.8 [95% CI:−1.0, −0.6] | 26 |
Spinal NP | 40 | 1 | Placebo | Significant VAS reduction | 28 |
Myofascial | 332 | 8 | Placebo | n.s. | 24 |
PSSP | 86 | 5 | Placebo | 0–10 VAS: −1.2 [95% CI:−2.4, −0.1] | 29 |
ASP | 40 | 1 | Placebo | 0–10 VAS −2.0 [95% CI:−3.7, −0.3] | 29 |
LE | 274 | 4 | Placebo | ES: −0.5 [95% CI:−0.9, −0.1] | 31 |
LBP | 131 | 3 | Mixedc | Meta-analysis not performed | 33 |
Ankle OA | 75 | 1 | HA | n.s. | 34 |
PF | 133 | 3 | Placebo | n.s. | 35 |
136 | 2 | Steroids | Pain relief: −0.7 [95% CI:−1.0, −0.3] | 35 | |
BPS | 317 | 6 | Placebo | 0–10 VAS −1.7 [95% CI:−3.2, −0.3] | 38 |